Skip to main content

Market Overview

Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation

Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
  • The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD).
  • Fulcrum is on track to report full data from the ReDUX4 Phase 2b trial at the virtual FSHD International Research Congress to be held next month.
  • Losmapimod previously received Orphan Drug Designation for FSHD.
  • Losmapimod is a selective p38α/β mitogen-activated protein kinase (MAPK) inhibitor exclusively in-licensed from GlaxoSmithKline plc (NYSE: GSK).
  • Evofem Biosciences Inc's (NASDAQ: EVFM) EVO100 to prevent urogenital gonorrhea in women also received the Fast Track tag from the FDA.
  • Phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea in women is currently enrolling.
  • The Company expects to complete enrollment by year-end 2021 and to report top-line data in mid-2022, with potential marketing application submission by the end of 2022.
  • EVO100 previously received the FDA Fast Track designation for the prevention of chlamydia in women. It was also designated as a Qualified Infectious Disease Product for the prevention of gonorrhea in women.
  • Price Action: FULC shares closed 0.38% lower at $10.40, while EVFM shares closed 0.81% higher at $1.25 on Wednesday.

Related Articles (EVFM + FULC)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Penny Stocks Health Care Small Cap FDA General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at